Treatment with the PARP inhibitor olaparib provided a significant benefit over standard therapy in patients with a BRCA GV and metastatic breast or pancreatic cancer [26, 66], and a high response rate in patients with ATM GVs and metastatic prostate cancer [49]. This evidence concerns the gene PARP1 and pancreatic neoplasm.